Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.992
Filter
2.
Surg Pathol Clin ; 17(2): 243-255, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38692808

ABSTRACT

Primary sarcoma of the lung and mediastinum is rare. The diagnosis requires careful exclusion of sarcomatoid carcinoma, sarcomatoid mesothelioma, and metastases from extra-thoracic sites. This review summarizes the key morphologic, immunohistochemical, and molecular characteristics of sarcomas that are encountered in the lung and mediastinum. The tumor types discussed are synovial sarcoma, well-differentiated/dedifferentiated liposarcoma, myxoid pleomorphic liposarcoma, intimal sarcoma of the pulmonary artery, inflammatory myofibroblastic tumor, epithelioid hemangioendothelioma, primary pulmonary myxoid sarcoma, malignant peripheral nerve sheath tumor, Ewing sarcoma, and CIC-rearranged sarcoma. Relevant differential diagnoses are also addressed.


Subject(s)
Lung Neoplasms , Mediastinal Neoplasms , Sarcoma , Humans , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/diagnosis , Sarcoma/pathology , Sarcoma/diagnosis , Diagnosis, Differential , Biomarkers, Tumor
3.
Surg Pathol Clin ; 17(2): 257-270, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38692809

ABSTRACT

Spindle cell lesions of the pleura and pericardium are rare. Distinction from sarcomatoid mesothelioma, which has a range of morphologic patterns, can be difficult, but accurate diagnosis matters. This article provides practical guidance for the diagnosis of pleural spindle cell neoplasms, focusing on primary lesions.


Subject(s)
Pericardium , Pleural Neoplasms , Humans , Pericardium/pathology , Pleural Neoplasms/pathology , Pleural Neoplasms/diagnosis , Diagnosis, Differential , Heart Neoplasms/pathology , Heart Neoplasms/diagnosis , Mesothelioma/pathology , Mesothelioma/diagnosis , Sarcoma/pathology , Sarcoma/diagnosis , Biomarkers, Tumor/analysis , Pleura/pathology
4.
J Int Med Res ; 52(5): 3000605241253756, 2024 May.
Article in English | MEDLINE | ID: mdl-38796313

ABSTRACT

Prostatic stromal tumors, encompassing prostatic sarcoma and stromal tumors of uncertain malignant potential (STUMP), represent an exceedingly rare category of prostatic diseases, with a prevalence of less than 1%. We present a rare case involving a man in his early 40s diagnosed with STUMP. Despite presenting with normal prostate-specific antigen (PSA) concentrations, the patient experienced persistent dysuria and gross hematuria for >7 months, leading to an initial misdiagnosis of benign prostatic hyperplasia. Persistent symptoms prompted further investigation, with magnetic resonance imaging (MRI) revealing a suspicious lesion on the left side of the prostate, initially thought to be malignant. Transrectal prostatic biopsy subsequently confirmed the presence of mucinous liposarcoma, with no medical history of diabetes, coronary heart disease, or hypertension. The treatment approach comprised robot-assisted laparoscopic radical prostatectomy, culminating in a postoperative pathological definitive diagnosis of STUMP. This case underscores the indispensable role of early MRI in the diagnostic process, highlighting the necessity of detailed pathological examination for a conclusive diagnosis. Our report aims to illuminate the diagnostic challenges and potential treatment pathways for STUMP, emphasizing its consideration in the differential diagnosis of prostatic tumors to advance clinical outcomes in this rare but important condition.


Subject(s)
Magnetic Resonance Imaging , Prostatic Neoplasms , Humans , Male , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/diagnostic imaging , Adult , Diagnosis, Differential , Prostatectomy , Prostate/pathology , Prostate/surgery , Prostate/diagnostic imaging , Prostate-Specific Antigen/blood , Prostatic Hyperplasia/surgery , Prostatic Hyperplasia/pathology , Prostatic Hyperplasia/diagnostic imaging , Prostatic Hyperplasia/diagnosis , Sarcoma/pathology , Sarcoma/surgery , Sarcoma/diagnosis , Sarcoma/diagnostic imaging
5.
Sci Rep ; 14(1): 12374, 2024 05 29.
Article in English | MEDLINE | ID: mdl-38811642

ABSTRACT

Circulating tumor cells (CTCs) have gathered attention as a biomarker for carcinomas. However, CTCs in sarcomas have received little attention. In this work, we investigated cell surface proteins and antibody combinations for immunofluorescence detection of sarcoma CTCs. A microfluidic device that combines filtration and immunoaffinity using gangliosides 2 and cell surface vimentin (CSV) antibodies was employed to capture CTCs. For CTC detection, antibodies against cytokeratins 7 and 8 (CK), pan-cytokeratin (panCK), or a combination of panCK and CSV were used. Thirty-nine blood samples were collected from 21 patients of various sarcoma subtypes. In the independent samples study, samples were subjected to one of three antibody combination choices. Significant difference in CTC enumeration was found between CK and panCK + CSV, and between panCK and panCK + CSV. Upon stratification of CK+ samples, those of metastatic disease had a higher CTC number than those of localized disease. In the paired samples study involving cytokeratin-positive sarcoma subtypes, using panCK antibody detected more CTCs than CK. Similarly, for osteosarcoma, using panCK + CSV combination resulted in a higher CTC count than panCK. This study emphasized deliberate selection of cell surface proteins for sarcoma CTC detection and subtype stratification for studying cancers as heterogeneous as sarcomas.


Subject(s)
Biomarkers, Tumor , Neoplastic Cells, Circulating , Sarcoma , Humans , Neoplastic Cells, Circulating/pathology , Neoplastic Cells, Circulating/metabolism , Sarcoma/pathology , Sarcoma/blood , Sarcoma/diagnosis , Sarcoma/metabolism , Biomarkers, Tumor/blood , Female , Male , Membrane Proteins/metabolism , Membrane Proteins/immunology , Keratins/immunology , Keratins/metabolism , Middle Aged , Adult , Vimentin/metabolism , Vimentin/immunology , Aged , Antibodies/immunology , Cell Line, Tumor
6.
Front Immunol ; 15: 1372692, 2024.
Article in English | MEDLINE | ID: mdl-38720884

ABSTRACT

Background: The tertiary lymphatic structure (TLS) is an important component of the tumor immune microenvironment and has important significance in patient prognosis and response to immune therapy. However, the underlying mechanism of TLS in soft tissue sarcoma remains unclear. Methods: A total of 256 RNAseq and 7 single-cell sequencing samples were collected from TCGA-SARC and GSE212527 cohorts. Based on published TLS-related gene sets, four TLS scores were established by GSVA algorithm. The immune cell infiltration was calculated via TIMER2.0 and "MCPcounter" algorithms. In addition, the univariate, LASSO, and multivariate-Cox analyses were used to select TLS-related and prognosis-significant hub genes. Single-cell sequencing dataset, clinical immunohistochemical, and cell experiments were utilized to validate the hub genes. Results: In this study, four TLS-related scores were identified, and the total-gene TLS score more accurately reflected the infiltration level of TLS in STS. We further established two hub genes (DUSP9 and TNFSF14) prognosis markers and risk scores associated with soft tissue sarcoma prognosis and immune therapy response. Flow cytometry analysis showed that the amount of CD3, CD8, CD19, and CD11c positive immune cell infiltration in the tumor tissue dedifferentiated liposarcoma patients was significantly higher than that of liposarcoma patients. Cytological experiments showed that soft tissue sarcoma cell lines overexpressing TNFSF14 could inhibit the proliferation and migration of sarcoma cells. Conclusion: This study systematically explored the TLS and related genes from the perspectives of bioinformatics, clinical features and cytology experiments. The total-gene TLS score, risk score and TNFSF14 hub gene may be useful biomarkers for predicting the prognosis and immunotherapy efficacy of soft tissue sarcoma.


Subject(s)
Biomarkers, Tumor , Immunotherapy , Sarcoma , Tumor Microenvironment , Humans , Sarcoma/genetics , Sarcoma/therapy , Sarcoma/immunology , Sarcoma/diagnosis , Biomarkers, Tumor/genetics , Prognosis , Immunotherapy/methods , Tumor Microenvironment/immunology , Tumor Microenvironment/genetics , Gene Expression Regulation, Neoplastic , Female , Male , Tumor Necrosis Factor Ligand Superfamily Member 14/genetics , Gene Expression Profiling , Single-Cell Analysis
7.
J Int Med Res ; 52(5): 3000605241255504, 2024 May.
Article in English | MEDLINE | ID: mdl-38759217

ABSTRACT

Retroperitoneal spindle cell neoplasms are diagnostically challenging. Malignant peripheral nerve sheath tumours (MPNSTs) can sometimes present as sporadic primary retroperitoneal tumours. MPNSTs are usually high-grade and highly aggressive tumours and are associated with a poor prognosis. Low-grade MPNSTs are very rarely described. This current case report describes a case of sporadic primary low-grade MPNST presenting as retroperitoneal spindle cell neoplasm. The diagnosis, imaging and immunohistopathological findings, as well as its successful surgical management, are presented.


Subject(s)
Nerve Sheath Neoplasms , Retroperitoneal Neoplasms , Humans , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/surgery , Retroperitoneal Neoplasms/diagnostic imaging , Nerve Sheath Neoplasms/pathology , Nerve Sheath Neoplasms/diagnosis , Nerve Sheath Neoplasms/surgery , Male , Middle Aged , Diagnosis, Differential , Neoplasm Grading , Sarcoma/diagnosis , Sarcoma/pathology , Sarcoma/surgery , Sarcoma/diagnostic imaging , Tomography, X-Ray Computed , Female
8.
J Cardiothorac Surg ; 19(1): 288, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38745263

ABSTRACT

Pulmonary arterial sarcomas (PAS) are rare aggressive tumours occurring mainly in the pulmonary trunk. We report a case of PAS involving the pulmonary trunk wall and valve, with uniform wall thickening which represents an atypical imaging manifestation of this tumour. A 63-year-old male presented with vague respiratory symptoms with rapid progression. CTPA showed low density filling defects in both pulmonary arteries and PET scan showed increased uptake in the pulmonary trunk, which along with raised ESR suggested Pulmonary Vasculitis. Echo imaging showed Right ventricular hypertrophy and pulmonary stenosis. Response to steroid therapy was minimal and his symptoms worsened. A referral for second opinion was made and he was diagnosed with PAS. He underwent Pulmonary thromboendarterectomy with Pulmonary valve replacement. Post-operative histopathology confirmed the diagnosis. PAS is rare and frequently misdiagnosed. Surgical resection is not curative, but together with chemotherapy can prolong survival.


Subject(s)
Pulmonary Artery , Pulmonary Valve , Sarcoma , Vascular Neoplasms , Humans , Male , Middle Aged , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/surgery , Pulmonary Artery/pathology , Sarcoma/diagnosis , Sarcoma/surgery , Pulmonary Valve/diagnostic imaging , Vascular Neoplasms/diagnosis , Vascular Neoplasms/surgery , Vascular Neoplasms/diagnostic imaging , Diagnosis, Differential , Vasculitis/diagnosis , Diagnostic Errors
9.
Rev Prat ; 74(4): 409-410, 2024 Apr.
Article in French | MEDLINE | ID: mdl-38814037
10.
J Stomatol Oral Maxillofac Surg ; 125(2): 101656, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38738551

ABSTRACT

Oral metastatic sarcomas (OMSs) occur only occasionally, and information about their characteristics is based on the restricted number of cases reported in the literature. This study aims to systematically review the English literature to recognize the clinicopathologic characteristics of OMSs. An electronic search was performed in PubMed Central and Scopus databases. The search included all the published articles (human case reports and case series) up till April 2023, with no time restrictions. OMSs were slightly more prevalent in males in their fifth to seventh decades of life. However, a high percentage of OMSs has been reported in the second decade of life. Lower extremities, breasts and uterus are the most common primary origin of metastatic sarcoma. Gingiva and mandible were common locations in the oral cavity for metastatic deposits. Generally, they demonstrated widespread affliction. The mean time interval between primary tumor detection and diagnosis of the oral metastasis was about 33.54 ± 36.19 months. Death was reported in 83 patients (67.48 %) with a mean survival rate of 7.98 ± 10.30 months. The most common microscopic tumor types were leiomyosarcoma (n = 21, 17 %), followed by angiosarcoma (n = 20, 16.26 %) and osteosarcoma (n = 18, 14.63 %). In conclusion, while oral metastases of sarcomas are not common, those should be considered in the differential diagnosis of the oral lesions. Although OMSs show a high occurrence in the 7th decade of the life, the average age of patients with oral involvement is lower than the overall metastatic lesions. OMSs may present as widespread disease with poor prognosis.


Subject(s)
Mouth Neoplasms , Sarcoma , Humans , Mouth Neoplasms/pathology , Mouth Neoplasms/diagnosis , Mouth Neoplasms/epidemiology , Sarcoma/diagnosis , Sarcoma/pathology , Sarcoma/secondary , Sarcoma/epidemiology , Female , Male
11.
World J Surg Oncol ; 22(1): 104, 2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38637834

ABSTRACT

OBJECTIVES: To investigate the clinicopathological characteristics and prognosis of patients with primary sarcoma of the uterine cervix. METHODS: We identified all patients with primary cervical sarcomas treated at our institution from 2002 to 2020 and analyzed the clinicopathological characteristics and prognosis. RESULTS: 34 patients were identified, 7 (20.6%) patients had leiomyosarcoma, 6 (17.6%) had carcinosarcoma, 5 (14.7%) had Ewing sarcoma, 4 (11.8%) had rhabdomyosarcoma, 4 (11.8%) had undifferentiated sarcoma, 2 (5.9%) had adenosarcoma, 2 (5.9%) had endometrial stromal sarcoma, 1 (2.9%) had dermatofibrosarcoma protuberans, 1 (2.9%) had alveolar soft tissue sarcoma and 2 (5.9%) had sarcoma not otherwise specified. The median age of the whole patients was 43.5 years (range, 13-63). The median age of patients with Ewing sarcoma or rhabdomyosarcoma was 22 years (range, 13-39) and 17 years (range, 13-36 years), respectively. The distribution by stage was: stage I in 21 (61.8%) patients, stage II in 4 (11.8%), stage III in 6 (17.6%) and stage IV in 3 (8.8%). Overall, 30 patients (88.2%) received surgical treatment. The median follow-up was 33.3 months (range 3.6-187.3 months). 11 patients died within 2 years after diagnosis, most of them were patients with carcinosarcoma or undifferentiated sarcoma (45.5%, 5/11). In the entire cohort, 2- and 5-year OS were 67.2% and 56.9%, respectively. 5-year OS was 25.0% for undifferentiated sarcoma, 50.0% for rhabdomyosarcoma, 50.0% for carcinosarcoma, 53.3% for Ewing sarcoma, 57.1% for leiomyosarcoma. CONCLUSION: Cervical sarcomas are rare neoplasms with multiple histological subtypes and follow an aggressive course. Prognosis may be associated with tumor histology and stage.


Subject(s)
Carcinosarcoma , Leiomyosarcoma , Rhabdomyosarcoma , Sarcoma, Ewing , Sarcoma , Uterine Cervical Neoplasms , Uterine Neoplasms , Female , Humans , Adolescent , Young Adult , Adult , Middle Aged , Leiomyosarcoma/pathology , Sarcoma, Ewing/surgery , Uterine Cervical Neoplasms/surgery , Uterine Neoplasms/diagnosis , Sarcoma/surgery , Sarcoma/diagnosis , Carcinosarcoma/pathology , Rhabdomyosarcoma/surgery , Prognosis
12.
Cancer Rep (Hoboken) ; 7(4): e2065, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38627902

ABSTRACT

BACKGROUND: Extrapleural pneumonectomy (EPP) is a complex surgical procedure involving en-bloc resection of the parietal and visceral pleura, lung, pericardium, and ipsilateral diaphragm. Small case series of pleural-based sarcoma of predominantly pediatric patients suggest EPP may be a life-prolonging surgical option. We aimed to describe the characteristics and outcomes of adults who underwent EPP at a specialized sarcoma center. METHODS: Clinicopathologic variables, surgical details, and follow-up information were extracted for patients undergoing EPP for pleural-based sarcoma between August 2017 and December 2020. Primary outcomes were event-free survival (EFS) and overall survival (OS) from the date of EPP. Secondary outcomes were disease-free interval (DFI) prior to EPP, and early and late postoperative complications. RESULTS: Eight patients were identified, seven with soft tissue sarcoma and one with bone sarcoma. Patients had either localized disease with a primary thoracic sarcoma, sarcoma recurrent to the thorax, or de novo metastatic disease. All patients underwent resection of their pleural-based sarcoma by an experienced cardiothoracic surgeon, and some patients had pre or postoperative treatment. The perioperative morbidity was comparable with previously published reports of EPP performed in mesothelioma patients. At median follow-up of 22.5 months, median EFS was 6.0 months and OS was 20.7 months. Six patients (75%) had disease recurrence; five (62.5%) died of progressive disease. Two patients (25%) had not recurred: one died of a radiation-related esophageal rupture, and one was alive with no evidence of disease at 37.0 months. Characteristics of those with the longest EFS included low-grade histology and achieving a metabolic response to preoperative chemotherapy. CONCLUSIONS: In adults with pleural-based sarcoma, EPP is rarely curative but appears to be a feasible salvage procedure when performed at specialized centers. Patient selection is critical with strong consideration given to multimodal therapy to optimize patient outcomes. In the absence of a confirmed response to neoadjuvant treatment, long term survival is poor and EPP should not be recommended.


Subject(s)
Mesothelioma , Pleural Neoplasms , Sarcoma , Adult , Humans , Child , Pneumonectomy/adverse effects , Pneumonectomy/methods , Pleural Neoplasms/diagnosis , Pleural Neoplasms/surgery , Neoplasm Recurrence, Local , Mesothelioma/pathology , Mesothelioma/surgery , Sarcoma/diagnosis , Sarcoma/surgery
13.
Ann Ital Chir ; 95(2): 119-125, 2024.
Article in English | MEDLINE | ID: mdl-38684493

ABSTRACT

INTRODUCTION: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare and aggressive malignant tumor, with nonspecific clinical symptoms and radiological features. Less than 150 cases have been reported in adults across the world. PRESENTATION OF CASE: We report a case of an extremely rare subtype of UESL with epithelioid features in a 29-year-old woman, presenting as a cystic lesion of 27 × 17 cm, completely subverting the right hepatic lobe. She underwent a right hepatectomy with anterior approach, complete hilum lymphadenectomy and partial diaphragmatic resection for local infiltration, followed by systemic chemotherapy. She remains with no evidence of disease and liver mass has been restored after 6 months. DISCUSSION: The present case report represents the second case of UESL with epithelioid features described across the world. The immunohistochemical expression pattern, cytokeratin (CK)19 + and CK7 -, strongly suggests an origin of this epithelioid component from native biliary cells and not from a reshaped ductal plate. Due to the rarity of this form, to date it is impossible to define the prognostic impact of this subtype of UESL, and treatment remains challenging. CONCLUSION: UESL is associated with a poor prognosis, especially in adults, but a comprehensive and multidisciplinary treatment based on radical resection and adjuvant therapy may provide a survival benefit. Surgical excision with negative margins remains mandatory to diagnose and treat UESL.


Subject(s)
Hepatectomy , Liver Neoplasms , Rare Diseases , Sarcoma , Humans , Adult , Female , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Sarcoma/pathology , Sarcoma/surgery , Sarcoma/diagnosis , Neoplasms, Germ Cell and Embryonal/pathology , Neoplasms, Germ Cell and Embryonal/surgery , Epithelioid Cells/pathology
14.
Mol Biol Rep ; 51(1): 568, 2024 Apr 24.
Article in English | MEDLINE | ID: mdl-38656400

ABSTRACT

BACKGROUND: Tumor embolism is a very rare primary manifestation of cancers and the diagnosis is challenging, especially if located in the pulmonary arteries, where it can mimic nonmalignant pulmonary embolism. Intimal sarcoma is one of the least commonly reported primary tumors of vessels with only a few cases reported worldwide. A typical location of this malignancy is the pulmonary artery. Herein, we present a case report of an intimal sarcoma with primary manifestation in the pulmonary arteries. A 53-year-old male initially presented with dyspnea. On imaging, a pulmonary artery embolism was detected and was followed by thrombectomy of the right ventricular outflow tract, main pulmonary artery trunk, and right pulmonary artery after ineffective lysis therapy. Complementary imaging of the chest and abdomen including a PET-CT scan demonstrated no evidence of a primary tumor. Subsequent pathology assessment suggested an intimal sarcoma further confirmed by DNA methylation based molecular analysis. We initiated adjuvant chemotherapy with doxorubicin. Four months after the completion of adjuvant therapy a follow-up scan revealed a local recurrence without distant metastases. DISCUSSION: Primary pulmonary artery intimal sarcoma (PAS) is an exceedingly rare entity and pathological diagnosis remains challenging. Therefore, the detection of entity-specific molecular alterations is a supporting argument in the diagnostic spectrum. Complete surgical resection is the prognostically most important treatment for intimal cardiac sarcomas. Despite adjuvant chemotherapy, the prognosis of cardiac sarcomas remains very poor. This case of a PAS highlights the difficulty in establishing a diagnosis and the aggressive natural course of the disease. CONCLUSION: In case of atypical presentation of a pulmonary embolism, a tumor originating from the great vessels should be considered. Molecular pathology techniques support in establishing a reliable diagnosis.


Subject(s)
Pulmonary Artery , Sarcoma , Thrombosis , Humans , Male , Middle Aged , Pulmonary Artery/pathology , Sarcoma/diagnosis , Sarcoma/pathology , Tunica Intima/pathology , Vascular Neoplasms/diagnosis , Vascular Neoplasms/pathology , Pulmonary Embolism/diagnosis , Diagnosis, Differential
15.
Arkh Patol ; 86(2): 37-41, 2024.
Article in Russian | MEDLINE | ID: mdl-38591905

ABSTRACT

Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion is an extremely rare tumor. Its clinical manifestation is unspecific and only molecular genetic method can proof this diagnosis. This paper describes an unusual clinical presentation of primary pulmonary myxoid sarcoma in a 68-year-old patient with involvement of both lungs.


Subject(s)
Lung Neoplasms , Sarcoma , Humans , Aged , Sarcoma/genetics , Sarcoma/diagnosis , Lung/pathology , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Oncogene Proteins, Fusion/genetics , Cyclic AMP Response Element-Binding Protein/genetics , RNA-Binding Protein EWS/genetics
16.
Expert Rev Anticancer Ther ; 24(6): 407-421, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38682679

ABSTRACT

INTRODUCTION: Soft tissue sarcomas (STS) are a rare and diverse group of tumors. Curative options are limited to localized disease, with surgery being the mainstay. Advanced stages are associated with a poor prognosis. Currently, the prognosis of the patient is based on histological classification and clinical characteristics, with only a few biomarkers having entered clinical practice. AREAS COVERED: This article covers extensive recent research that has established novel potential biomarkers based on genomics, proteomics, and clinical characteristics. Validating and incorporating these biomarkers into clinical practice can improve prognosis, prediction of recurrence, and treatment response. Relevant literature was collected from PubMed, Scopus, and clinicaltrials.gov databases (November 2023). EXPERT OPINION: Currently, defining prognostic markers in soft tissue sarcomas remains challenging. More studies are required, especially to personalize treatment through advanced genetic profiling and analysis using individual tumor and patient characteristics.


Subject(s)
Biomarkers, Tumor , Genomics , Proteomics , Sarcoma , Humans , Sarcoma/pathology , Sarcoma/genetics , Sarcoma/diagnosis , Sarcoma/therapy , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Prognosis , Genomics/methods , Neoplasm Recurrence, Local , Precision Medicine , Neoplasm Staging , Soft Tissue Neoplasms/pathology , Soft Tissue Neoplasms/genetics , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/therapy
17.
Crit Rev Oncol Hematol ; 197: 104354, 2024 May.
Article in English | MEDLINE | ID: mdl-38614268

ABSTRACT

Preoperative biopsy for retroperitoneal sarcoma (RPS) enables appropriate multidisciplinary treatment planning. A systematic review of literature from 1990 to June 2022 was conducted using the population, intervention, comparison and outcome model to evaluate the local recurrence and overall survival of preoperative biopsy compared to those that had not. Of 3192 studies screened, five retrospective cohort studies were identified. Three reported on biopsy needle tract seeding, with only one study reporting biopsy site recurrence of 2 %. Two found no significant difference in local recurrence and one found higher 5-year local recurrence rates in those who had not been biopsied. Three studies reported overall survival, including one with propensity matching, did not show a difference in overall survival. In conclusion, preoperative core needle biopsy of RPS is not associated with increased local recurrence or adverse survival outcomes.


Subject(s)
Neoplasm Recurrence, Local , Retroperitoneal Neoplasms , Sarcoma , Humans , Australia/epidemiology , Biopsy , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/epidemiology , New Zealand/epidemiology , Practice Guidelines as Topic , Preoperative Care/standards , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/mortality , Retroperitoneal Neoplasms/surgery , Retroperitoneal Neoplasms/diagnosis , Sarcoma/mortality , Sarcoma/pathology , Sarcoma/diagnosis , Sarcoma/therapy
18.
Medicina (Kaunas) ; 60(4)2024 Mar 27.
Article in English | MEDLINE | ID: mdl-38674190

ABSTRACT

Sarcomas, particularly undifferentiated small round cell sarcomas of bone and soft tissue, pose significant diagnostic challenges due to their nonspecific morphology and the necessity for comprehensive molecular analyses. This paper discusses a rare case of round cell sarcoma exhibiting the EWSR1-CREM fusion, offering insights into the complexities of its diagnosis and management. The patient, a 15-year-old female with a history of Type 1 diabetes, presented with persistent right thigh tenderness and swelling. MRI revealed a large necrotic mass in the retroperitoneal region. Histological analysis showed a well-demarcated tumor with diverse cellular morphologies and distinct necrotic areas. Immunohistochemical (IHC) tests identified dot-like staining for Desmin and Vimentin but negative results for several markers, including Cytokeratin and CD45. Strong ALK positivity was noted. Next-generation sequencing with the Illumina TruSight™ Oncology 500 assay revealed the fusion gene EWSR1-CREM, along with benign and uncertain mutations in other genes. The tumor's morphology and immunoprofile, along with molecular findings, led to a diagnosis of round cell sarcoma with EWSR1-CREM fusion. This case adds to the spectrum of tumors associated with this fusion, often presenting diverse morphologies. The rarity of EWSR1-CREM fusion sarcomas poses a challenge in treatment, highlighted by the development of pulmonary metastases and disease progression after surgical excision in this patient despite the lack of an effective targeted therapy. In conclusion, this case emphasizes the need for a multidisciplinary diagnostic approach in complex sarcomas and highlights the importance of continued research on rare sarcomas, their genetic underpinnings, and potential therapeutic targets.


Subject(s)
Cyclic AMP Response Element Modulator , RNA-Binding Protein EWS , Sarcoma , Humans , Female , Sarcoma/genetics , Sarcoma/diagnosis , Sarcoma/surgery , RNA-Binding Protein EWS/genetics , Adolescent
19.
Eur J Surg Oncol ; 50(6): 108271, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38522331

ABSTRACT

INTRODUCTION: Primary bone tumors encompass a range of rare and diverse lesions. Pathological diagnosis poses significant challenges, with histological discrepancies extensively studied in soft tissue sarcomas but lacking specific investigation in bone lesions. This study aimed to determine the rate of major diagnostic discrepancies in primary bone tumors, assessing whether initial histological analysis within an expert referral center network reduces this rate and final diagnostic delay. Additionally, we examined the impact of mandatory systematic re-reading by expert pathologists on diagnostic variation and readjustment. METHODS: Our study cohort comprised patients with primary bone tumors, drawn from the national prospective French sarcoma network database. A total of 1075 patients were included from 2018 to 2019. RESULTS: The cohort exhibited a major discrepancy rate of 24%. Within the expert referral centers network, 49 cases (7%) showed major diagnostic discrepancies in the initial analysis, compared to 207 cases (57%) outside the network (p < 0.001). Regarding the final diagnostic delay, a mean of 2.8 weeks (±4.9) was observed within the network, contrasting with 6.5 weeks (±9.1) outside the network (p < 0.001). Systematic re-reading by an expert pathologist facilitated diagnosis readjustment in 75% of the 256 cases, with 68% of all diagnostic variations occurring preoperatively. CONCLUSION: Early management within the expert network significantly reduced major diagnostic discrepancies and shortened the diagnosis delay by approximately a month. Expert pathologist systematic re-readings were responsible for diagnosis readjustments in three-quarters of cases, with two-thirds of all diagnostic variations occurring preoperatively, thereby mitigating the consequences of mistreatment.


Subject(s)
Bone Neoplasms , Delayed Diagnosis , Sarcoma , Humans , Bone Neoplasms/diagnosis , Bone Neoplasms/pathology , Female , Male , Sarcoma/diagnosis , Sarcoma/pathology , Middle Aged , Adult , France , Aged , Adolescent , Diagnostic Errors/statistics & numerical data , Child , Referral and Consultation , Young Adult
20.
Pathologica ; 116(1): 46-54, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38482674

ABSTRACT

Objective: Small series and individual cases of penile soft tissue tumours are reported in the literature: these are rare tumours that represent less than 5% of all penile tumours. Methods: Penile soft tissue tumours were collected from the archive of the Department of Pathology at the Istituto Nazionale dei Tumori of Milan between January 1990 and October 2021. All available medical records were retrieved and reviewed to obtain clinical information. Results: Our series refers to the 30-year experience of highlighting the heterogeneity in the presentation and microscopic features of these rare sarcomas. 18 penile soft tissue tumours are described, 4 benign and 14 malignant. The mean age at diagnosis was 58.2 years (range 24-96 years) and 53.6 years among malignancies (range 24-89). The most frequent histotype was Kaposi's sarcoma (nr = 4) and very unusual histotypes were observed, namely low-grade fibromyxoid sarcoma, synovial sarcoma, proximal type epithelioid sarcoma and the first reported case of dedifferentiated liposarcoma of the penis. Conclusions: Among sarcomas of the genitourinary tract, tumours of the soft tissues of the penis are the rarest. Penile sarcomas can present at a young age. Kaposi's sarcoma in HIV-negative patients has a favorable outcome, while deep sarcomas have an aggressive behavior and poor prognosis.


Subject(s)
Penile Neoplasms , Sarcoma, Kaposi , Sarcoma , Soft Tissue Neoplasms , Male , Humans , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Sarcoma, Kaposi/diagnosis , Sarcoma, Kaposi/epidemiology , Sarcoma, Kaposi/pathology , Penile Neoplasms/diagnosis , Penile Neoplasms/epidemiology , Penile Neoplasms/surgery , Sarcoma/diagnosis , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/pathology , Penis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...